Drugs A - Z

tretinoin oral Images

Generic Name: tretinoin oral

Brand Names: Vesanoid

There is an FDA Alert for this drug. Click here to view it.

    Limit to Qualified Personnel
  • Administer only to patients with acute promyelocytic leukemia (APL) under the strict supervision of a qualified clinician experienced in the management of patients with acute leukemia.
  • Appropriate diagnostic and treatment facilities must be readily available in case the patient develops severe toxicity, including respiratory compromise.
  • Use only when the potential benefits are thought to outweigh the possible risks of therapy.

    Retinoic Acid-APL (RA-APL) Syndrome
  • Clinical manifestations of the syndrome (fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural and pericardial effusions, edema, and hepatic, renal, and multiorgan failure), with or without leukocytosis, have occurred in about 25% of patients.
  • Occasionally accompanied by impaired myocardial contractility and episodic hypotension.
  • Progressive hypoxemia has required endotracheal intubation and mechanical ventilation and may be fatal (due to multiorgan failure).
  • High-dose corticosteroid therapy administered at first suspicion of the syndrome may reduce morbidity or mortality. (See RA-APL Syndrome under Cautions.)

    Leukocytosis
  • Rapidly evolving leukocytosis occurs in approximately 40% of patients and is associated with an increased risk of life-threatening complications.
  • High leukocyte count (i.e., >5000/mm3) at diagnosis increases risk of further rapid increase of leukocyte count.
  • Initiate high-dose corticosteroid treatment immediately if leukocytosis and signs or symptoms of RA-APL syndrome are present together.
  • Consider adding full-dose chemotherapy (including an anthracycline) to tretinoin. (See Leukocytosis under Cautions.)

    Teratogenic Effects
  • Known teratogen; special precautions and instruction are necessary in women of childbearing potential or pregnant women receiving the drug. (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
  • Inform patients of the risks of fetal harm and contraceptive failure.

The Healthline Site, its content, such as text, graphics, images, search results, HealthMaps, Trust Marks, and other material contained on the Healthline Site ("Content"), its services, and any information or material posted on the Healthline Site by third parties are provided for informational purposes only. None of the foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately. Please read the Terms of Service for more information regarding use of the Healthline Site.
Advertisement
Advertisement